{{Rsnum
|rsid=7168987
|Gene=RORA
|Chromosome=15
|position=60982234
|Orientation=plus
|GMAF=0.2107
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=RORA
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 61.1 | 29.2 | 9.7
| HCB | 89.8 | 10.2 | 0.0
| JPT | 87.6 | 11.5 | 0.9
| YRI | 52.4 | 38.1 | 9.5
| ASW | 50.9 | 43.9 | 5.3
| CHB | 89.8 | 10.2 | 0.0
| CHD | 90.8 | 9.2 | 0.0
| GIH | 67.3 | 31.7 | 1.0
| LWK | 52.7 | 39.1 | 8.2
| MEX | 56.9 | 39.7 | 3.4
| MKK | 37.8 | 48.7 | 13.5
| TSI | 58.8 | 32.4 | 8.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7168987
|Name_s=
|Gene_s=RORA
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109455
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7168987
|overall_frequency_n=23
|overall_frequency_d=128
|overall_frequency=0.179688
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}